Heart failure with preserved ejection fraction (HFpEF) - Pipeline Insight, 2024

Heart failure with preserved ejection fraction (HFpEF) - Pipeline Insight, 2024

DelveInsight’s, “Heart failure with preserved ejection fraction (HFpEF) - Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Heart failure with preserved ejection fraction (HFpEF) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Heart failure with preserved ejection fraction (HFpEF) Understanding

Heart failure with preserved ejection fraction (HFpEF): Overview

Heart failure with preserved ejection fraction (HFpEF)) occurs when the lower left chamber (left ventricle) is not able to fill properly with blood during the diastolic (filling) phase. The amount of blood pumped out to the body is less than normal. It is also called diastolic heart failure. The types of heart failure are based on a measurement called the ejection fraction. The ejection fraction measures how much blood inside the ventricle is pumped out with each contraction. The left ventricle squeezes and pumps some (but not all) of the blood in the ventricle out to your body. A normal ejection fraction is more than 55%. This means that 55% of the total blood in the left ventricle is pumped out with each heartbeat. Heart failure with preserved ejection fraction (HFpEF)) happens when the left ventricle is not filling with blood as well as normal. The ventricle can pump well. But it may be stiff so it cannot relax and fill with blood as well as normal. The ejection fraction is 50% or more. HFpEF may also be diagnosed if the ejection fraction is 40% to 49%.footnote

""Heart failure with preserved ejection fraction (HFpEF) - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart failure with preserved ejection fraction (HFpEF) pipeline landscape is provided which includes the disease overview and Heart failure with preserved ejection fraction (HFpEF) treatment guidelines. The assessment part of the report embraces, in depth Heart failure with preserved ejection fraction (HFpEF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart failure with preserved ejection fraction (HFpEF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Heart failure with preserved ejection fraction (HFpEF) R&D. The therapies under development are focused on novel approaches to treat/improve Heart failure with preserved ejection fraction (HFpEF).

Heart failure with preserved ejection fraction (HFpEF) Emerging Drugs Chapters

This segment of the Heart failure with preserved ejection fraction (HFpEF) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Heart failure with preserved ejection fraction (HFpEF) Emerging Drugs

• Tirzepatide: Eli Lilly and Company

Tirzepatide (LY3298176, Dual GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of chronic heart failure with preserved ejection fraction. Currently, it is in phase III stage of clinical trial evaluation to treat Heart failure with preserved ejection fraction (HFpEF)).

• Semaglutide: Novo Nordisk A/S

Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. GLP-1 is a physiological hormone that promotes glycemic control via several different mechanisms, including insulin secretion, slowing gastric emptying, and reducing postprandial glucagon secretion. The homeostasis of glucose is dependent on hormones such as insulin and amylin, which are secreted by the beta cells of the pancreas. Semaglutide is 94% similar to human GLP-1. Analogs of this hormone such as semaglutide stimulate the synthesis of insulin by stimulating pancreatic islet cells and reducing glucagon secretion. They directly bind with selectivity to the GLP-1 receptor, causing various beneficial downstream effects that reduce blood glucose in a glucose-dependent fashion. Currently, it is in phase III stage of clinical trial evaluation to treat Heart failure with preserved ejection fraction (HFpEF)).

Further product details are provided in the report……..

Heart failure with preserved ejection fraction (HFpEF): Therapeutic Assessment

This segment of the report provides insights about the different Heart failure with preserved ejection fraction (HFpEF) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Heart failure with preserved ejection fraction (HFpEF)

There are approx. 12+ key companies which are developing the therapies for Heart failure with preserved ejection fraction (HFpEF). The companies which have their Heart failure with preserved ejection fraction (HFpEF) drug candidates in the most advanced stage, i.e. phase III include, Eli Lilly and Company.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Heart failure with preserved ejection fraction (HFpEF) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Heart failure with preserved ejection fraction (HFpEF): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart failure with preserved ejection fraction (HFpEF) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart failure with preserved ejection fraction (HFpEF) drugs.

Heart failure with preserved ejection fraction (HFpEF) Report Insights

• Heart failure with preserved ejection fraction (HFpEF) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Heart failure with preserved ejection fraction (HFpEF) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Heart failure with preserved ejection fraction (HFpEF) drugs?
• How many Heart failure with preserved ejection fraction (HFpEF) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart failure with preserved ejection fraction (HFpEF)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart failure with preserved ejection fraction (HFpEF) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Heart failure with preserved ejection fraction (HFpEF) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eli Lilly and Company
• Novo Nordisk
• Actelion Pharmaceuticals
• AstraZeneca
• Palatin Technologies
• MyoKardia, Inc.
• Stealth BioTherapeutics Inc.
• Pfizer
• Asklepios Biopharmaceutical, Inc.
• Cardiol Therapeutics
• Gilead Sciences
• Bayer
• Tenaya Therapeutics

Key Products

• Tirzepatide
• Semaglutide
• Macitentan
• AZD4831
• Dapagliflozin
• PL-3994
• Mavacamten
• elamipretide
• Sildenafil
• NAN-101
• CardiolRx™100
• Ranolazine hydrochloride
• Empagliflozin
• Finerenone
• TYA 11631